مباشر
FierceBiotechAvalyn aims for $182M IPO to fund phase 3 trials of reformulated respiratory drugsThermo FisherThermo Fisher Scientific Q1 Earnings Call Highlights - Yahoo FinanceAgilentDoes Agilent (A) Settling Axion Dispute Clarify Its Push Into Cloud Lab Data Recurring Revenues? - simplywall.st10x Genomics BlogWhy 10x Genomics (TXG) Shares Are Trading Lower Today - Yahoo Finance10x Genomics BlogLiquidCell Dx Appoints Former Foundation Medicine, 10x Genomics and IDT Leader Mirna Jarosz as Chief Executive Officer; Names Former Foundation Medicine Chief Medical Officer Vincent A. Miller, MD, Senior Strategic Advisor - BioSpaceThermo FisherThermo Fisher Scientific: Why A Slow Q1 Does Not Reflect The Growth Opportunities - Seeking AlphaMOONS'How Artemis will help the U.S. create a moon base - NBC NewsAgilentAgilent Technologies Inc (A) Shares Fall 5.0% -- What GF Score o - GuruFocusThermo FisherThermo Fisher Scientific Inc. stock falls Thursday, underperforms market - MarketWatchFierceBiotechDespite data concerns, Roche’s oral SERD can still be largest product in company history: execFierceBiotechRegeneron ushers in new genetic medicine era with groundbreaking gene therapy approvalThermo FisherThermo Fisher CEO says onshoring push will bring a ‘tailwind’ for the Waltham company - The Business Journals
Endpoints News ١٦ ديسمبر ٢٠٢٥

Mythic Therapeutics shuts down, ends ADC trial as funding dries up

Mythic Therapeutics shuts down, ends ADC trial as funding dries up

المصدر
المحتوى غير متاح. يرجى الرجوع إلى المصدر الأصلي.